Amgen Halts Early Obesity Drug, Focuses on MariTide

Amgen recently stopped the development of AMG 513. This drug was an early-stage treatment for obesity. The company now places all its hopes on MariTide, another drug in its pipeline.

MariTide is much further along in its testing. It is currently in Phase 3 trials. This means it is being tested in many people to confirm it is safe and effective. The obesity drug market is growing quickly. Amgen wants a large part of this market.

The decision to drop AMG 513 highlights Amgen's plan. They are putting resources into their most promising treatments. This move means MariTide faces increased pressure. It must perform well to secure Amgen's position in the competitive weight-loss field.

This news shows how drug companies make tough choices. They constantly evaluate their drug candidates. These decisions help them bring the best new medicines to people who need them.

Source: FierceBiotech